49
Participants
Start Date
February 1, 2024
Primary Completion Date
November 30, 2027
Study Completion Date
November 30, 2027
Pembrolizumab
Pembrolizumab will be administered on an every 3-week dosing schedule
Trastuzumab
Trastuzumab will be administered on an every 3-week dosing schedule
Oxaliplatin
Oxaliplatin every 3 weeks, +/-7 days
Capecitabine
Capecitabine twice daily on days 1 to 14 every 3 weeks or 5-FU on days 1 to 5 every 3 weeks
5-Fluorouracil
5-Fluorouracil administered as a 24 hour IV continuous infusion once every 2 weeks
Docetaxel
Docetaxel administered intravenously once every 2 weeks.
RECRUITING
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
RECRUITING
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
RECRUITING
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale
RECRUITING
Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity), Commack
RECRUITING
University of Pennsylvania (Data Collection Only), Philadelphia
RECRUITING
MD Anderson Cancer Center (Data Collection Only), Houston
RECRUITING
Massachusetts General Hospital (Data Collection Only), Boston
RECRUITING
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
RECRUITING
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
RECRUITING
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
Collaborators (1)
Genentech, Inc.
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER